ES2111524T3 - Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos. - Google Patents

Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.

Info

Publication number
ES2111524T3
ES2111524T3 ES90113527T ES90113527T ES2111524T3 ES 2111524 T3 ES2111524 T3 ES 2111524T3 ES 90113527 T ES90113527 T ES 90113527T ES 90113527 T ES90113527 T ES 90113527T ES 2111524 T3 ES2111524 T3 ES 2111524T3
Authority
ES
Spain
Prior art keywords
epo
antibodies
peptides
epitope
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90113527T
Other languages
English (en)
Inventor
Mathias Dr Fibi
Werner Dr Stueber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behring Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behring Diagnostics GmbH filed Critical Behring Diagnostics GmbH
Application granted granted Critical
Publication of ES2111524T3 publication Critical patent/ES2111524T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

EL INVENTO CONCIERNE A LOS PEPTIDOS DE ERITROPOYETINA (EPO) Y A SU UTILIZACION PARA LA OBTENCION DE ANTICUERPOS EPITOPESPECIFICOS ANTI-EPO, LOS CUALES PUEDEN SER POLICLONES (ANTISUEROS) O MONOCLONES. TAMBIEN SE REFIERE EL INVENTO AL USO DE DICHOS ANTICUERPOS PARA LA PURIFICACION DEL EPO, DE LOS DERIVADOS DEL EPO O DE LOS EPO-PEPTIDOS. CONCIERNE TAMBIEN A LOS ANTICUERPOS ANTIIDIOTIPOS QUE IMITAN UNA ZONA RECEPTORA DEL EPO. POR ULTIMO, SE REFIERE A LA UTILIZACION DE REFIERE A LA UTILIZACION DE LOS ANTICUERPOS EPITOPESPECIFICOS ANTI-EPO PARA DETECTAR LA PRESENCIA DE EPO EN MEDICAMENTOS QUE CONTENGAN LOS CITADOS ANTICUERPOS Y PARA DIAGNOSTICAR LA PRESENCIA DE EPO O DE ANTICUERPOS ANTI-EPO.
ES90113527T 1989-07-26 1990-07-14 Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos. Expired - Lifetime ES2111524T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3924746A DE3924746A1 (de) 1989-07-26 1989-07-26 Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper

Publications (1)

Publication Number Publication Date
ES2111524T3 true ES2111524T3 (es) 1998-03-16

Family

ID=6385895

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90113527T Expired - Lifetime ES2111524T3 (es) 1989-07-26 1990-07-14 Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.

Country Status (13)

Country Link
US (2) US5106954A (es)
EP (1) EP0410246B1 (es)
JP (1) JP3155002B2 (es)
KR (1) KR0175657B1 (es)
AT (1) ATE161577T1 (es)
AU (1) AU648506B2 (es)
CA (1) CA2021912C (es)
DE (2) DE3924746A1 (es)
DK (1) DK0410246T3 (es)
ES (1) ES2111524T3 (es)
GR (1) GR3026096T3 (es)
IE (1) IE902707A1 (es)
PT (1) PT94813B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6932968B1 (en) * 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB2270695B (en) * 1992-09-18 1996-06-05 Oxford Res Support Co Ltd Antibodies that activate plasminogen in the manner of streptokinase
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
CA2223833C (en) * 1995-06-07 2010-12-21 Nicholas C. Wrighton Compounds and peptides that bind to the erythropoietin receptor
KR100400637B1 (ko) * 1996-02-06 2004-03-10 씨제이 주식회사 생물학적으로유용한펩타이드
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
WO1999028346A1 (de) * 1997-12-03 1999-06-10 Roche Diagnostics Gmbh Erythropoietin mit hoher spezifischer aktivität
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
MXPA01011264A (es) * 1999-05-07 2002-07-02 Genentech Inc Nuevos polipeptidos de eritropoyetina de chimpance (chepo) y aciodos nucleicos que codifican los mismos.
KR100524041B1 (ko) * 1999-05-07 2005-10-27 제넨테크, 인크. 신규 침팬지 에리쓰로포이에틴 (chepo) 폴리펩티드 및 이를 코딩하는 핵산
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
CA2405029A1 (en) * 2000-04-05 2001-10-18 Jong Y. Lee Detection of erythropoietin and erythtropoietin receptor
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US20040063917A1 (en) * 2001-02-06 2004-04-01 Carr Francis J. Modified erythropoietin (epo) with reduced immunogenicity
WO2002070009A1 (en) * 2001-02-27 2002-09-12 Yasuda, Yoshiko Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
ES2261458T3 (es) * 2001-07-26 2006-11-16 Tagra Biotechnologies Ltd Derivados estabilizados del aciddo ascorbico 3-fosfato.
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
PL372862A1 (en) * 2002-08-09 2005-08-08 Merck Patent Gmbh T-cell epitopes in erythropoietin
CA2521273A1 (en) * 2003-04-02 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US20040266993A1 (en) * 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
BRPI0518025A (pt) * 2004-11-10 2008-10-28 Aplagen Gmbh moléculas que promovem hematopoiese
US7589063B2 (en) * 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
CA2586915A1 (en) * 2004-11-10 2006-05-18 Aplagen Gmbh Molecules which promote hematopoiesis
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
EP2385061A3 (en) 2005-05-10 2012-02-22 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
WO2006136450A2 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
SG170086A1 (en) * 2006-03-09 2011-04-29 Aplagen Gmbh De Modified molecules which promote hematopoiesis
WO2008112703A2 (en) * 2007-03-12 2008-09-18 University Of Utah Research Foundation Compositions and methods for diagnosing and treating diabetic micro vascular complications
KR20200075044A (ko) * 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
DK2928921T3 (da) * 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4558005A (en) * 1982-09-13 1985-12-10 University Patents, Inc. Monoclonal anti-erythropoietin
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions

Also Published As

Publication number Publication date
KR0175657B1 (ko) 1999-04-01
KR910002897A (ko) 1991-02-26
DE59010787D1 (de) 1998-02-05
IE902707A1 (en) 1991-02-27
PT94813B (pt) 1997-04-30
EP0410246B1 (de) 1997-12-29
DK0410246T3 (da) 1998-08-31
PT94813A (pt) 1991-03-20
AU5977890A (en) 1991-01-31
CA2021912A1 (en) 1991-01-27
CA2021912C (en) 2001-11-27
ATE161577T1 (de) 1998-01-15
US5712370A (en) 1998-01-27
DE3924746A1 (de) 1991-01-31
AU648506B2 (en) 1994-04-28
EP0410246A1 (de) 1991-01-30
JPH0381294A (ja) 1991-04-05
GR3026096T3 (en) 1998-05-29
JP3155002B2 (ja) 2001-04-09
US5106954A (en) 1992-04-21

Similar Documents

Publication Publication Date Title
ES2111524T3 (es) Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.
ES2082775T4 (es) Anticuerpos de proteinas latentes de papilomavirus humano, sistemas de diagnostico y procedimientos.
WO1996029605A3 (en) Compounds and methods for the dectection of t. cruzi infection
FI913560A7 (fi) Synteettiset peptidit, erikoisesti HCV:n vasta-aineiden havaitsemiseen, HCV infektion diagnoosiin ja sen estämiseen rokotteina
DE3874493D1 (de) Optischer positionssensor, den faraday-effekt benutzend.
DE69006391D1 (de) Gassensor.
NO910209D0 (no) Fremgangsmaate for fremstilling av rekombinante humane anti-cd18 antistoffer.
NO870476D0 (no) Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater.
FI944225L (fi) Diagnostisia reagensseja EBV:n vasta-aineiden detektoimiseksi
DK172686A (da) Antigen opnaaet ud fra humant vaev, fremgangsmaade til under anvendelse af antigenet at fremstille monoklonale antistoffer til diagnose og behandling af cancer, fremgangsmaade til paavisning af cancer, samt antistoffer mod antigenet
FI885868A7 (fi) Menetelmä immuunikatoviruksen vasta-aineiden havaitsemiseksi
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
DE68903882D1 (de) Immunochemisches testverfahren fuer humanen granulozyten-makrophagen-kolonie stimulierenden faktor.
FI873606A7 (fi) Ihmisen glykoalbumiinin määrittämiseen käyttökelpoisia vasta-aineita.
DE69228739D1 (de) Immunoassay und monoklonaler antikörper zum nachweis von diarrhetischem schalentiergift
ES1009600Y (es) Dispositivo de fijacion de elementos sensores.
EP1212407A4 (en) POLYNUCLEOTIDES, POLYPEPTIDES AND ANTIBODIES OF THE IMMUNOGLOBULIN SUPER FAMILY
EP0600000A4 (en) HEPATITIS C DETECTION TEST USING RECOMBINANT ANTIGENS OF THE NS5 REGION.
ZA903854B (en) Diagnostic test for detecting antibodies directed against antigens of one or more related viruses
FI891417A7 (fi) Apparat foer utfoerande av ett diagnostiskt test.
DK362087D0 (da) Method for a rapid and sensitive detection of early appearing antibodies against retroviruses, as well as igg antibodies against certain retroviruses
NO900092L (no) Et ekspresjonssystem for fremstilling av kimeriske monoklonale antistoffer.
IL83422A (en) Method for the detection of human b lymphotropic virus antibodies
NO912050D0 (no) Sensor for optisk undersoekelse.
NO890775D0 (no) Apparat for testing av utblaasningssikring.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 410246

Country of ref document: ES